论文部分内容阅读
目的探讨急性白血病(AL)血清乳酸脱氢酶(LDH)与α羟丁酸脱氢酶(α-HBDH)的临床价值。方法初诊AL患者231例(A组)中,143例为完全缓解(A1组),31例出现缓解后复发(A2组),A组根据白细胞数分为高白细胞(C1)组、白细胞正常(C2)组和低白细胞(C3)组。另设正常人群101例作为对照(B组)。采用酶学法检测各组血清LDH和α-HBDH水平。结果 A组血清LDH和α-HBDH浓度为604.6U/L和455.59U/L,明显高于B组的194.93U/L和144.48U/L(P<0.05);A2组血清LDH和α-HBDH浓度为390.46U/L和282.12U/L,明显高于B组和A1组的221.25U/L和163.76U/L(P<0.05)。C1组血清LDH和α-HBDH浓度为785.83U/L和584.26U/L,明显高于C2组的466.17U/L和363.41U/L和C3组的318.43U/L和246.5U/L(P<0.05)。A组中,急性淋巴细胞白血病患者的血清LDH和α-HBDH浓度为992.01U/L和757.33U/L,明显高于急性髓细胞白血病患者的497.66U/L和372.44U/L(P<0.05)。结论血清LDH和α-HBDH可作为AL诊治过程中判断病情变化和预测复发的参考指标。
Objective To investigate the clinical value of serum lactate dehydrogenase (LDH) and α-hydroxybutyrate dehydrogenase (α-HBDH) in acute leukemia (AL). Methods A total of 231 AL patients (group A) received complete remission (group A1) and complete remission (group A2). A group was divided into high white blood cell group (C1) and white blood cell group C2) group and low white blood cell (C3) group. Another 101 cases of normal population as a control (B group). Serum LDH and α-HBDH levels were detected by enzymatic method. Results Serum concentrations of LDH and α-HBDH in group A were 604.6U / L and 455.59U / L, which were significantly higher than those in group B (194.93U / L and 144.48U / L, respectively) The concentrations were 390.46U / L and 282.12U / L, which were significantly higher than 221.25U / L and 163.76U / L in group B and group A1 (P <0.05). The concentrations of LDH and α-HBDH in C1 group were 785.83U / L and 584.26U / L, which were significantly higher than 466.17U / L and 363.41U / L in C2 group and 318.43U / L and 246.5U / L in C3 group <0.05). In group A, serum LDH and α-HBDH levels in patients with acute lymphoblastic leukemia were 992.01U / L and 757.33U / L, significantly higher than those of patients with acute myeloid leukemia (497.66U / L and 372.44U / L, respectively, P <0.05 ). Conclusions Serum LDH and α-HBDH can be used as a reference index for judging the change of disease and predicting relapse during the diagnosis and treatment of AL.